Document/ExhibitDescriptionPagesSize 1: 8-K Current Report HTML 30K
2: EX-99.1 Miscellaneous Exhibit HTML 14K
6: R1 Cover HTML 47K
9: XML IDEA XML File -- Filing Summary XML 11K
7: XML XBRL Instance -- apen-20220329_htm XML 22K
8: EXCEL IDEA Workbook of Financial Reports XLSX 6K
4: EX-101.LAB XBRL Labels -- apen-20220329_lab XML 69K
5: EX-101.PRE XBRL Presentations -- apen-20220329_pre XML 34K
3: EX-101.SCH XBRL Schema -- apen-20220329 XSD 10K
10: JSON XBRL Instance as JSON Data -- MetaLinks 12± 17K
11: ZIP XBRL Zipped Folder -- 0001251769-22-000026-xbrl Zip 16K
(Address of principal executive offices) (Zip Code)
(i512) i279-5100
(Registrant’s
telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
i☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
iIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
iCommon
stock, $0.001 par value per share
iAPEN
iThe Nasdaq Global Market
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective March 29, 2022, Jeannette Bankes was appointed to the Board of Directors (the “Board”) of Apollo Endosurgery, Inc. (the “Company”), filling an existing vacancy. Ms. Bankes will serve as a Class II director, and her term will expire at the 2022 annual meeting of stockholders unless re-elected. The Board has determined that Ms. Bankes is an independent director pursuant to the listing standards of The Nasdaq Stock Market LLC (“Nasdaq”).
There are no arrangements or understandings between Ms. Bankes and any other persons pursuant to which she was selected as a director, and there is no family relationship between Ms. Bankes and any other members of the
Board or the Company’s executive officers. There are no related person transactions (within the meaning of Item 404(a) of Regulation S-K) between Ms. Bankes and the Company.
In connection with her appointment to the Board, and in accordance with the Company’s Non-Employee Director Compensation Policy, (i) Ms. Bankes will be granted, pursuant to the Company’s 2017 Equity Incentive Plan (the “Plan”), an initial stock option and restricted stock unit award to acquire the Company’s common stock
at a later date, valued at $55,000 in the aggregate, and (ii) the Company will pay Ms. Bankes an annual retainer of $35,000 for service as a member of the Board. The stock option will have an exercise price equal to the closing price of the Company’s common stock as reported on Nasdaq on the date the stock option is granted. The Plan and related forms of stock option agreement and restricted stock unit award are filed as Exhibits 10.1, 10.2 and 10.3, respectively, to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission (the “SEC”) on June 13, 2017.
The
Company will enter into an indemnity agreement with Ms. Bankes in connection with her services as a member of the Board. The form of indemnity agreement is filed as Exhibit 10.6 to the Company’s Quarterly Report on Form 10-Q, filed with the SEC on August 8, 2018.
The press release attached to this report as Exhibit 99.1 is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information contained in the press release attached to this report as Exhibit 99.1 shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by us, whether made before or after the date hereof, regardless of any general
incorporation language in such filing.
Cover
Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
